135 related articles for article (PubMed ID: 19352275)
21. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
22. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
23. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
[TBL] [Abstract][Full Text] [Related]
24. Staging performance of carbon-11 choline positron emission tomography/computed tomography in patients with bone and soft tissue sarcoma: comparison with conventional imaging.
Tateishi U; Yamaguchi U; Maeda T; Seki K; Terauchi T; Kawai A; Arai Y; Moriyama N; Kakizoe T
Cancer Sci; 2006 Oct; 97(10):1125-8. PubMed ID: 16925579
[TBL] [Abstract][Full Text] [Related]
25. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
26. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors.
Gerth HU; Juergens KU; Dirksen U; Gerss J; Schober O; Franzius C
J Nucl Med; 2007 Dec; 48(12):1932-9. PubMed ID: 18006618
[TBL] [Abstract][Full Text] [Related]
27. [Combined FDG PET/CT imaging for restaging of colorectal cancer patients: impact of image fusion on staging accuracy].
Strunk H; Bucerius J; Jaeger U; Joe A; Flacke S; Reinhardt M; Hortling N; Palmedo H
Rofo; 2005 Sep; 177(9):1235-41. PubMed ID: 16123869
[TBL] [Abstract][Full Text] [Related]
28. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
29. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT.
Comoretto M; Balestreri L; Borsatti E; Cimitan M; Franchin G; Lise M
Radiology; 2008 Oct; 249(1):203-11. PubMed ID: 18710963
[TBL] [Abstract][Full Text] [Related]
30. Detection of bone metastases: assessment of integrated FDG PET/CT imaging.
Taira AV; Herfkens RJ; Gambhir SS; Quon A
Radiology; 2007 Apr; 243(1):204-11. PubMed ID: 17392254
[TBL] [Abstract][Full Text] [Related]
31. Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas.
Bélissant O; Champion L; Thevenet H; Weinmann P; Alberini JL
Nucl Med Commun; 2018 Jul; 39(7):652-658. PubMed ID: 29683931
[TBL] [Abstract][Full Text] [Related]
32. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer.
Gearhart SL; Frassica D; Rosen R; Choti M; Schulick R; Wahl R
Ann Surg Oncol; 2006 Mar; 13(3):397-404. PubMed ID: 16485158
[TBL] [Abstract][Full Text] [Related]
33. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18.
Basu D; Siegel BA; McDonald DJ; Nussenbaum B
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):801-5. PubMed ID: 17709620
[TBL] [Abstract][Full Text] [Related]
34. PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin.
Katal S; Gholamrezanezhad A; Kessler M; Olyaei M; Jadvar H
PET Clin; 2018 Oct; 13(4):609-621. PubMed ID: 30219191
[TBL] [Abstract][Full Text] [Related]
35. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
36. [Clinical application of (18)F-FDG PET/CT to staging and treatment effectiveness monitoring of nasopharyngeal carcinoma].
Wang GH; Lau EW; Shakher R; Binns DS; Hogg A; Drummond E; Hicks RJ
Ai Zheng; 2007 Jun; 26(6):638-42. PubMed ID: 17562272
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas.
Tateishi U; Hosono A; Makimoto A; Sakurada A; Terauchi T; Arai Y; Imai Y; Kim EE
J Pediatr Hematol Oncol; 2007 Sep; 29(9):608-12. PubMed ID: 17805034
[TBL] [Abstract][Full Text] [Related]
38. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
39. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET).
Kut V; Spies W; Spies S; Gooding W; Argiris A
Am J Clin Oncol; 2007 Feb; 30(1):45-50. PubMed ID: 17278894
[TBL] [Abstract][Full Text] [Related]
40. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
